Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on DANSKE BANK A S. We currently have 6 research reports from 1 professional analysts.
|09Feb17 09:29||GNW||Danske Bank A/S: Form 8.3 - Sepura Plc|
|03Feb17 08:39||GNW||Danske Bank A/S: Form 8.3 - Sepura Plc|
|02Feb17 10:54||GNW||Danske Bank A/S: Form 8.3 - Sepura Plc|
|27Jan17 12:14||GNW||Danske Bank A/S : Form 8.3 - Sepura Plc|
|20Jan17 11:11||GNW||CORRECTION: Danske Bank A/S: Form 8.3 - Sepura Plc|
|16Jan17 18:12||GNW||Danske Bank A/S: Form 8.3 - Sepura Plc|
|07Nov16 14:10||GNW||Danske Bank A/S: Form 8.3 - Sepura Plc|
Frequency of research reports
Research reports on
DANSKE BANK A S
DANSKE BANK A S
Strong set of results (P&L and capital)
02 Feb 17
Danske bank announced its Q4 16 earnings results this morning: Total income at DKK12.9bn was 7% above expectations and still 3.7% above when adjusted for total revenues for volatile trading and other income. Total expenses were 2.4% higher than expected but loan losses were a bit lower. All in all, profit before tax at DKK7.04bn was 35% higher than forecasts and 11% higher when stripping out trading and other revenues. The CET1 ratio at 16.3% is 50bp higher qoq (above management’s requirements of 14-15%). A DKK10bn share buy-back programme has just been announced. We had expected a lower number at DKK6bn.
The unexpected costs of inflation are a drag...
21 Jul 16
Total revenues for Q2 16 were 3% higher than expectations, driven mainly by strong trading income. Operating leverage was somewhat offset by higher expenses than forecast even if loan losses were lower than what had been expected. On the solvency side, the CET1 ratio is at 15.8% or 80bp higher than last quarter.
A ray of sunshine emerging from Denmark...
03 Feb 16
Danske bank annouced its Q415 earnings release this morning: Both revenues and profit before tax have beaten consensus expectations confirming recovery in the Danish economy. And with a CET ratio 40bps higher than Q315 (and 4.3% higher than the SREP requirements), Danske bank announced a DKK9bn buy-back programme starting Q116.
Strong Q2 15 earnings release
22 Jul 15
Danske Bank released it Q2 15 earnings results. Total revenues are in line with consensus (DKK10,968m vs DKK10,896m) but profit before tax is 20% higher than expected (DKK5.874m vs DKK4,929m). The net profit target has been revised upwards as management expects 2015 earnings to top DKK16bn. Basel III CET1 is at 13.3% or 30bp higher than in Q1 15.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
Small Cap Breakfast
23 Mar 17
K3 Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march.
Small Cap Breakfast
21 Mar 17
First Sentinel—Investment company expecting NEX admission/introduction on 24 March. £636k raised pre-IPO. BioPharma Credit—Expected Gross Initial Acquisition Proceeds now c.$338m. Gross Cash Proceeds capped at $423m with placing and open offer. Results expected 23 March with admission now due 30 march. Tufton Oceanic Assets- The Company intends to invest in a diversified portfolio of second hand commercial sea-going vessels where the Investment Manager believes that an attractive opportunity exists in shipping. $150m raise. Admission 3 April.
N+1 Singer - Morning Song 23-03-2017
23 Mar 17
eg solutions (EGS LN) Re-focusing on sales is delivering rewards | Futura Medical (FUM LN) FY results: continued clinical, regulatory and commercial progress | Halfords Group (HFD LN) Confidence in FX mitigation grows; stay at BUY | IFG Group (IFP LN) Top line growth but earnings pressures remain | Realm Therapeutics (RLM LN) FY results in line; on track for Phase II start in 2017 | Safestyle UK (SFE LN) Another good full year performance but valuation up with events | WYG (WYG LN) Mixed conclusion to FY17, reassuring FY18 outlook